🇺🇸 FDA
Patent

US 10653652

Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction

granted A61KA61K31/196A61P

Quick answer

US patent 10653652 (Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction) held by OVID THERAPEUTICS INC. expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/196, A61P, A61P27/16